Methods of preparing novel dipeptide compounds or...

Details Methods of preparing novel dipeptide compounds or... Methods of preparing novel dipeptide compounds or...

1999-01-08

2001-04-24

Ceperley, Mary E. (Department: 1641)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S235500, C514S236800, C514S326000, C514S343000, C514S422000, C514S423000, C544S141000, C544S333000, C546S208000, C546S209000, C548S215000, C548S269200, C548S265800, C548S265800, C548S517000, C548S518000, C548S540000

Reexamination Certificate

active

06222043

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to the synthesis of novel dipeptide compounds having an inhibitory action against enzymatic activity of protease derived from HIV virus. More specifically, it relates to the synthesis of novel dipeptide compounds having an acyl group of a monocyclic carboxylic acid linked to an amino group of the N-terminal of the dipeptide. In addition, the present invention relates to methods of using the dipeptide compounds and pharmaceutically acceptable salts thereof.
BACKGROUND OF THE INVENTION
Human immunodeficiency virus (hereinafter referred to HIV) which causes AIDS produces a precursor protein comprising Gag protein used for the formation of the said virus particles and reverse transcriptase in host cells. This precursor protein is cleaved by a protease (hereinafter referred to HIV protease) derived from the virus into a specific size to perform its function. Therefore, an HIV protease inhibitor exhibits antiviral activity by inhibiting an enzymatic activity of HIV protease to block the formation and maturation of infectious virus particles. Several kinds of HIV protease inhibitors have been already reported, comprising synthetic peptide-like compound called as a transition-state mimetic (T. Robins, J. Plattner, J. Acquir. Immun. Defic. Syndr. 6, 162 (1993)). Hydroxyethylamine type derivatives such as Ro 31-8959 comprising phenylalanine &psgr;[CH(OH)CH
2
N] decahydroisoquinoline carboxylic acid skeleton similar to the amino acid sequence -Tyr . . . Pro- or -Phe . . . Pro- as a cleavage site of the HIV protease (N. A. Roberts et al., Science 248, 358-361 (1990)) and hydroxymethylcarboxamide type derivatives such as peptide derivatives comprising a norstatine skeleton phenylalanine &psgr;[CH(OH)C(O)N] proline were reported to be useful as a HIV protease inhibitor (T. F. Tam et al., J. Med. Chem. 35, 1318-1320 (1992)).
The present inventors also found that a group of synthetic peptides which were transition-state mimetic comprising 3-amino-2-hydroxy-4-phenylbutanoyl residue as the skeletal structure thereof strongly inhibited HIV protease activity to be useful as an anti-AIDS agent and proposed them as HIV protease inhibitors (Japanese laid-open patent No. 170722/1993).
These transition-state mimetics are considered as the most promising anti-AIDS agent of next generation following reverse transcriptase inhibitors of nucleic acid derivatives, such as AZT (azide thymidine), DDC (dideoxycytidine), DDI (dideoxyinosine), which are already used clinically as anti-AIDS agents and clinical use, clinical tests and researches thereof are in progress. That is, clinical application of HIV protease inhibitors has been tried to suppress the formation of virus particles in host cell and prevent the proliferation and infection of HIV, resulting in the prevention of onset of AIDS (Nakajima et al., Gekkan-Yakuji, vol. 35, 2983-2989 (1993)).
However, among these peptide-like compounds, conventional-type of compounds belonging to hydroxymethylcarboxamide derivatives exhibiting excellent HIV protease inhibitory activity have hydrophobic acyl group at N-terminal amino group of tripeptide chain. Therefore, in many cases, problems, such as, (1) their insolubility in water, (2) unstability in vivo, (3) low oral absorptivity have been reported (Hiroaki Mitsuya, Kagaku, vol. 64, No. 7, p462-470 (1994)). Since anti-AIDS agents are consecutively administered for long duration, development of compound with higher bioavailability, that is, easily absorbed and stable in vivo, especially in the case of oral administration has been desired. Development of a peptide compound with excellent HIV protease inhibitory activity which has a low molecular weight and is resistant against degradation by various kinds of digestive enzymes or proteolytic enzymes, is desired. More specifically development of a novel peptide compound with a small size of acyl group linked to N-terminal amino group which comprises only low molecular weight dipeptide-structure as transition-state mimetic is desired.
SUMMARY OF THE INVENTION
An object of the present invention is to provide a novel dipeptide compound which has nearly the same anti-HIV protease inhibitory activity as that of a transition-state mimetic peptide compound having a tripeptide chain and has a lower molecular weight than that. The object of the present invention is to provide a novel dipeptide compound which is different from various types of hydroxymethylcarboxamide tripeptide compound designed as a conventional HIV protease inhibitor with respect to peptide chain length and exhibit an excellent HIV protease inhibitory activity or suppressive action on the proliferation of HIV virus. Another object of the present invention is to provide a suppressive agent against HIV virus proliferation comprising a novel dipeptide compound as an effective ingredient.
The present inventors studied eagerly to design and prepare a novel dipeptide compound which has a clearly different structure from that of a conventional hydroxymethylcarboxamide-type peptide compound. The present inventors investigated whether or not these dipeptide compounds have a HIV protease inhibitory activity as designed and found that they exhibited excellent activities and accomplished the present invention.
Accordingly, the present invention provided novel dipeptide compounds having chemical structures described as the following items (1)-(6) and a suppressive action on HIV virus proliferation in vivo. In particular, the present invention provides a synthetic methodology for the synthesis of the dipeptide compounds disclosed herein.
(1) A novel dipeptide compound represented in general formula (I) or a pharmaceutically acceptable salt thereof.
(wherein R
1
represents 5-membered or 6-membered monocyclic hydrocarbon group, or heterocyclic group wherein more than one carbon atom in said monocyclic hydrocarbon can be substituted by hetero atoms comprising 3 or less substituted group in said cyclic group, X represents a methylene group (—CH
2
—), a chloromethylene group (—CH(Cl)—), an oxygen atom, a sulfur atom or sulfonyl group (—SO
2
—), R
21
and R
22
each represent a hydrogen atom or an aliphatic hydrocarbon having 1-6 carbons which can be linear or branched. R
3
represents an aliphatic hydrocarbon group having 1-6 carbons which can be linear or branched or a monovalent group derived from an aromatic monocyclic hydrocarbon wherein the sum of carbon number thereof is 12 or less, and halogen atoms can be substituted in aromatic ring of said aromatic monocyclic hydrocarbon group).
(2) A novel dipeptide compound represented in general formula (II) or a pharmaceutically acceptable salt thereof.
(wherein X, R
21
, R
22
and R
3
represents the same group as that in the above general formula (I), respectively. R
11
represents a hydrogen atom, an amino group or a hydroxy group. R
12
represents a hydrogen atom or aliphatic hydrocarbon group having 1-4 carbons which can be linear or branched).
(3) A novel dipeptide compound represented in general formula (III) or a pharmaceutically acceptable salt thereof.
(wherein X, R
21
and R
22
represents the same group as that in the above general formula (I), and R
11
and R
12
represents the same group as that in the above general formula (II)).
(4) A novel dipeptide compound represented in general formula (IV) or a pharmaceutically acceptable salt thereof.
(wherein X, R
21
and R
22
represents the same group as that in the above general formula (I), and R
11
and R
12
represents the same group as those in the above general formula (II). R
31
, R
32
and R
33
each represents a hydrogen atom, a halogen atom or an aliphatic hydrocarbon having 1-4 carbons which can be linear or branched).
(5) A novel dipeptide compound represented in general formula (V) or a pharmaceutically acceptable salt thereof.
(wherein R
11
represents an amino group or a hydroxy group. R
12
represents a methyl group or an ethyl group. R
21
and R
22
each represents a hydrogen atom or a methyl group).
(6) A novel dipeptide compo

Affiliated with

Also associated with

Rating

Methods of preparing novel dipeptide compounds or... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of preparing novel dipeptide compounds or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of preparing novel dipeptide compounds or... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2497685